It’s two years since Novartis got its Cosentyx IL-17 drug approved for the spinal disease ankylosing spondylitis, and the Swiss pharma company has new data that it hopes will allow it to compete ...

Please note Chef Michelle Bernstein is a COSENTYX® (secukinumab) patient and has been compensated for her time. Continue reading for Important Safety Information and a link to the full ...

Higher revenue from its key growth drivers—Entresto, immunology drug Cosentyx, breast-cancer treatment Kisqali and neuroscience medicine Kesimpta—offset a hit from generic competition and flat ...